Pedro Jesús Vidal Miñano


Pedro Jesús Vidal Miñano

Pedro Jesús Vidal holds a Biochemistry degree (University of Murcia, 2011) with the first cycle in chemistry, a Master in Molecular Biology and Biotechnology (University of Murcia, 2012), a PhD in Biomedicine (University of Barcelona, 2020) and a Postgraduate in Health innovation “d·Health Barcelona” (Moebio-Biocat, Barcelona, 2020).

During the last year of the Bachelor's degree, with a Collaboration Scholarship, and at the Master, he dealt and developed biomolecules with anti-inflammatory capacity. That work ended in the publication of a research article in a high impact journal. At 2013 and 2014, he worked at an environmental consulting, collaborated in the creation of a renewable energy Start-up, and also worked making organic synthesis for the pharmaceutical industry. After that, he won a FPI contract, for which he came to Barcelona in 2015 to start his doctoral thesis at the Molecular Biology Institute of Barcelona (IBMB-CSIC), and the University of Barcelona. He defended the thesis "Critical size: effects and implications on growth and cell cycle” in 2020. His research topics focused on molecular and cell biology, microbiology and genetic engineering (DNA, RNA, PCR, microscopy, and data and image analysis).

At the end of the doctorate, he wanted to expand his professional future towards clinical and translational research and innovation. So, last 2020 he performed the Postgraduate in health innovation “Design Health Barcelona”, from Moebio-BIOCAT. This program aims to develop leaders in innovation and entrepreneurship in the healthcare sector, and it is based on the methodologies of Biodesign, created by Stanford University, and Lean Start-up. There, the participants carry out a complete cycle of innovation: Identify an unmet clinical need, Identify a business idea, Design and Prototype a viable solution (medical device/app/service), and Develop a business model and search for funding. They developed “Damia Health”, a digital solution to support and help pregnant women and clinicians to early detect and prevent the first symptoms of perinatal depression.

In September 2021, he joined the Unit of Molecular Epidemiology and Genetics in Infections and Cancer at the Cancer Epidemiology Research Program (PREC) in the Catalan Institute of Oncology (ICO), with a project coordinator contract by IDIBELL, where he provided support in research activities and project management into the project “Effectiveness of HPV vaccination in the prevention of oral HPV infection in a young population” (PI: Alemany L. and Brotons M.)

On 2022, along with the previous project, he also join and support the SCREENWIDE (Screening signature of endometrial and ovarian cancers: options for early detection) and the RISCC (Risk-based Screening for Cervical Cancer, from the European Union) projects.

He is also involved in outreach activities on HPV and cervical cancer prevention and early detection methods, such as vaccination and screening.

Among others, he has participated in the educational project “VacunAcció” and on the Cancer Prevention Route during the Health Week in El Masnou.



Vidal PJ, López-Nicolás JM, Gandía-Herrero F, et al. Inactivation of lipoxygenase and cyclooxygenase by natural betalains and semi-synthetic analogues. Food Chem. 2014 Jul 1; 154:246–54. doi: 10.1016/j.foodchem.2014.01.014